OpenEvidence, maker of a popular chatbot that helps doctors search clinical evidence, on Wednesday announced $250 million in new funding.

The new round led by Thrive Capital and DST Global values OpenEvidence at $12 billion, and the company has announced $735 million in funding in the last 12 months. OpenEvidence is free to use by any clinician with a national provider identifier number. The company’s primary business model is advertising shown to clinicians. 

Founded in 2022, OpenEvidence is one of the most prominent and best-funded companies from a wave of health artificial intelligence companies that emerged since the widespread availability of large language models. Reflecting on the eye-popping fundraising for health AI, a Silicon Valley Bank report released earlier in January raised an eyebrow at the ability of companies like OpenEvidence to deliver on their stratospheric valuations with advertising and software-as-a-service business models. “It won’t be a surprise to see them tap the value of the data they’re already collecting” to offer more services to pharma or other customers, the authors wrote.

Continue to STAT+ to read the full story…

© Adobe

arXiv:2601.13122v1 Announce Type: new Abstract: Modern general-purpose AI systems made using large language and vision models, are capable of performing a range of tasks like writing text articles, generating and debugging codes, querying databases, and translating from one language to another, which has made them quite popular across industries. However, there are risks like hallucinations, toxicity, and stereotypes in their output that make them untrustworthy. We review various risks and vulnerabilities of modern general-purpose AI along eight widely accepted responsible AI (RAI) principles (fairness, privacy, explainability, robustness, safety, truthfulness, governance, and sustainability) and compare how they are non-existent or less severe and easily mitigable in traditional task-specific counterparts. We argue that this is due to the non-deterministically high Degree of Freedom in output (DoFo) of general-purpose AI (unlike the deterministically constant or low DoFo of traditional task-specific AI systems), and there is a need to rethink our approach to RAI for general-purpose AI. Following this, we derive C2V2 (Control, Consistency, Value, Veracity) desiderata to meet the RAI requirements for future general-purpose AI systems, and discuss how recent efforts in AI alignment, retrieval-augmented generation, reasoning enhancements, etc. fare along one or more of the desiderata. We believe that the goal of developing responsible general-purpose AI can be achieved by formally modeling application- or domain-dependent RAI requirements along C2V2 dimensions, and taking a system design approach to suitably combine various techniques to meet the desiderata.

arXiv:2601.13846v1 Announce Type: new Abstract: This paper introduces Virtual Urbanism (VU), a multimodal AI-driven analytical framework for quantifying urban identity through the medium of synthetic urban replicas. The framework aims to advance computationally tractable urban identity metrics. To demonstrate feasibility, the pilot study Virtual Urbanism and Tokyo Microcosms is presented. A pipeline integrating Stable Diffusion and LoRA models was used to produce synthetic replicas of nine Tokyo areas rendered as dynamic synthetic urban sequences, excluding existing orientation markers to elicit core identity-forming elements. Human-evaluation experiments (I) assessed perceptual legitimacy of replicas; (II) quantified area-level identity; (III) derived core identity-forming elements. Results showed a mean identification accuracy of ~81%, confirming the validity of the replicas. Urban Identity Level (UIL) metric enabled assessment of identity levels across areas, while semantic analysis revealed culturally embedded typologies as core identity-forming elements, positioning VU as a viable framework for AI-augmented urban analysis, outlining a path toward automated, multi-parameter identity metrics.

arXiv:2601.11544v1 Announce Type: cross Abstract: The introduction of large language models (LLMs) has greatly enhanced the capabilities of software agents. Instead of relying on rule-based interactions, agents can now interact in flexible ways akin to humans. However, this flexibility quickly becomes a problem in fields where errors can be disastrous, such as in a pharmacy context, but the opposite also holds true; a system that is too inflexible will also lead to errors, as it can become too rigid to handle situations that are not accounted for. Work using LLMs in a pharmacy context have adopted a wide scope, accounting for many different medications in brief interactions -- our strategy is the opposite: focus on a more narrow and long task. This not only enables a greater understanding of the task at hand, but also provides insight into what challenges are present in an interaction of longer nature. The main challenge, however, remains the same for a narrow and wide system: it needs to strike a balance between adherence to conversational requirements and flexibility. In an effort to strike such a balance, we present a prototype system meant to provide medication counseling while juggling these two extremes. We also cover our design in constructing such a system, with a focus on methods aiming to fulfill conversation requirements, reduce hallucinations and promote high-quality responses. The methods used have the potential to increase the determinism of the system, while simultaneously not removing the dynamic conversational abilities granted by the usage of LLMs. However, a great deal of work remains ahead, and the development of this kind of system needs to involve continuous testing and a human-in-the-loop. It should also be evaluated outside of commonly used benchmarks for LLMs, as these do not adequately capture the complexities of this kind of conversational system.

arXiv:2601.11567v1 Announce Type: cross Abstract: Small open-source medical large language models (LLMs) offer promising opportunities for low-resource deployment and broader accessibility. However, their evaluation is often limited to accuracy on medical multiple choice question (MCQ) benchmarks, and lacks evaluation of consistency, robustness, or reasoning behavior. We use MCQ coupled to human evaluation and clinical review to assess six small open-source medical LLMs (HuatuoGPT-o1 (Chen 2024), Diabetica-7B, Diabetica-o1 (Wei 2024), Meditron3-8B (Sallinen2025), MedFound-7B (Liu 2025), and ClinicaGPT-base-zh (Wang 2023)) in pediatric endocrinology. In deterministic settings, we examine the effect of prompt variation on models' output and self-assessment bias. In stochastic settings, we evaluate output variability and investigate the relationship between consistency and correctness. HuatuoGPT-o1-8B achieved the highest performance. The results show that high consistency across the model response is not an indicator of correctness, although HuatuoGPT-o1-8B showed the highest consistency rate. When tasked with selecting correct reasoning, both HuatuoGPT-o1-8B and Diabetica-o1 exhibit self-assessment bias and dependency on the order of the candidate explanations. Expert review of incorrect reasoning rationales identified a mix of clinically acceptable responses and clinical oversight. We further show that system-level perturbations, such as differences in CUDA builds, can yield statistically significant shifts in model output despite stable accuracy. This work demonstrates that small, semantically negligible prompt perturbations lead to divergent outputs, raising concerns about reproducibility of LLM-based evaluations and highlights the output variability under different stochastic regimes, emphasizing the need of a broader diagnostic framework to understand potential pitfalls in real-world clinical decision support scenarios.

arXiv:2601.12471v1 Announce Type: cross Abstract: Current evaluation of large language models (LLMs) overwhelmingly prioritizes accuracy; however, in real-world and safety-critical applications, the ability to abstain when uncertain is equally vital for trustworthy deployment. We introduce MedAbstain, a unified benchmark and evaluation protocol for abstention in medical multiple-choice question answering (MCQA) -- a discrete-choice setting that generalizes to agentic action selection -- integrating conformal prediction, adversarial question perturbations, and explicit abstention options. Our systematic evaluation of both open- and closed-source LLMs reveals that even state-of-the-art, high-accuracy models often fail to abstain with uncertain. Notably, providing explicit abstention options consistently increases model uncertainty and safer abstention, far more than input perturbations, while scaling model size or advanced prompting brings little improvement. These findings highlight the central role of abstention mechanisms for trustworthy LLM deployment and offer practical guidance for improving safety in high-stakes applications.

arXiv:2601.12607v1 Announce Type: cross Abstract: As Large Language Models (LLMs) become ubiquitous across various scientific domains, their lack of ability to perform complex tasks like running simulations or to make complex decisions limits their utility. LLM-based agents bridge this gap due to their ability to call external resources and tools and thus are now rapidly gaining popularity. However, coming up with a workflow that can balance the models, cloud providers, and external resources is very challenging, making implementing an agentic system more of a hindrance than a help. In this work, we present a domain-agnostic, model-independent workflow for an agentic framework that can act as a scientific assistant while being run entirely on cloud. Built with a supervisor agent marshaling an array of agents with individual capabilities, our framework brings together straightforward tasks like literature review and data analysis with more complex ones like simulation runs. We describe the framework here in full, including a proof-of-concept system we built to accelerate the study of Catalysts, which is highly important in the field of Chemistry and Material Science. We report the cost to operate and use this framework, including the breakdown of the cost by services use. We also evaluate our system on a custom-curated synthetic benchmark and a popular Chemistry benchmark, and also perform expert validation of the system. The results show that our system is able to route the task to the correct agent 90% of the time and successfully complete the assigned task 97.5% of the time for the synthetic tasks and 91% of the time for real-world tasks, while still achieving better or comparable accuracy to most frontier models, showing that this is a viable framework for other scientific domains to replicate.

arXiv:2601.12946v1 Announce Type: cross Abstract: Generative artificial intelligence (AI) is rapidly populating medical records with synthetic content, creating a feedback loop where future models are increasingly at risk of training on uncurated AI-generated data. However, the clinical consequences of this AI-generated data contamination remain unexplored. Here, we show that in the absence of mandatory human verification, this self-referential cycle drives a rapid erosion of pathological variability and diagnostic reliability. By analysing more than 800,000 synthetic data points across clinical text generation, vision-language reporting, and medical image synthesis, we find that models progressively converge toward generic phenotypes regardless of the model architecture. Specifically, rare but critical findings, including pneumothorax and effusions, vanish from the synthetic content generated by AI models, while demographic representations skew heavily toward middle-aged male phenotypes. Crucially, this degradation is masked by false diagnostic confidence; models continue to issue reassuring reports while failing to detect life-threatening pathology, with false reassurance rates tripling to 40%. Blinded physician evaluation confirms that this decoupling of confidence and accuracy renders AI-generated documentation clinically useless after just two generations. We systematically evaluate three mitigation strategies, finding that while synthetic volume scaling fails to prevent collapse, mixing real data with quality-aware filtering effectively preserves diversity. Ultimately, our results suggest that without policy-mandated human oversight, the deployment of generative AI threatens to degrade the very healthcare data ecosystems it relies upon.

arXiv:2601.13580v1 Announce Type: cross Abstract: We introduce Neural Organ Transplantation (NOT), a modular adaptation framework that enables trained transformer layers to function as reusable transferable checkpoints for domain adaptation. Unlike conventional fine-tuning approaches that tightly couple trained parameters to specific model instances and training data, NOT extracts contiguous layer subsets ("donor organs") from pre-trained models, trains them independently on domain-specific data, and saves them as standalone checkpoint files that can be transplanted into compatible recipient models without access to the original training data. Through experiments on three decoder-only transformer architectures spanning 124M to 20B parameters (GPT-2, TinyLlama, and GPT-OSS), we demonstrate that donor transplantation substantially outperforms existing adaptation methods, achieving an order-of-magnitude improvement in perplexity over LoRA while training significantly faster. The method exhibits position dependence, with early insertion positions yielding optimal results. Cross-domain transfer at billion-parameter scale reveals unexpected regularization benefits. These findings demonstrate that transformer middle layers can support efficient modular transfer for decoder-only architectures, enabling privacy-preserving expertise sharing through checkpoint distribution. We note that this approach is currently limited to decoder-only models; preliminary experiments on encoder-based architectures show reduced effectiveness.

arXiv:2601.13710v1 Announce Type: cross Abstract: Artificial intelligence has reshaped medical imaging, yet the use of AI on clinical data for prospective decision support remains limited. We study pre-operative prediction of clinically meaningful improvement in chronic rhinosinusitis (CRS), defining success as a more than 8.9-point reduction in SNOT-22 at 6 months (MCID). In a prospectively collected cohort where all patients underwent surgery, we ask whether models using only pre-operative clinical data could have identified those who would have poor outcomes, i.e. those who should have avoided surgery. We benchmark supervised ML (logistic regression, tree ensembles, and an in-house MLP) against generative AI (ChatGPT, Claude, Gemini, Perplexity), giving each the same structured inputs and constraining outputs to binary recommendations with confidence. Our best ML model (MLP) achieves 85 % accuracy with superior calibration and decision-curve net benefit. GenAI models underperform on discrimination and calibration across zero-shot setting. Notably, GenAI justifications align with clinician heuristics and the MLP's feature importance, repeatedly highlighting baseline SNOT-22, CT/endoscopy severity, polyp phenotype, and physchology/pain comorbidities. We provide a reproducible tabular-to-GenAI evaluation protocol and subgroup analyses. Findings support an ML-first, GenAI- augmented workflow: deploy calibrated ML for primary triage of surgical candidacy, with GenAI as an explainer to enhance transparency and shared decision-making.

arXiv:2509.05362v4 Announce Type: replace-cross Abstract: Scams exploiting real-time social engineering -- such as phishing, impersonation, and phone fraud -- remain a persistent and evolving threat across digital platforms. Existing defenses are largely reactive, offering limited protection during active interactions. We propose a privacy-preserving, AI-in-the-loop framework that proactively detects and disrupts scam conversations in real time. The system combines instruction-tuned artificial intelligence with a safety-aware utility function that balances engagement with harm minimization, and employs federated learning to enable continual model updates without raw data sharing. Experimental evaluations show that the system produces fluent and engaging responses (perplexity as low as 22.3, engagement $\approx$0.80), while human studies confirm significant gains in realism, safety, and effectiveness over strong baselines. In federated settings, models trained with FedAvg sustain up to 30 rounds while preserving high engagement ($\approx$0.80), strong relevance ($\approx$0.74), and low PII leakage ($\leq$0.0085). Even with differential privacy, novelty and safety remain stable, indicating that robust privacy can be achieved without sacrificing performance. The evaluation of guard models (LlamaGuard, LlamaGuard2/3, MD-Judge) shows a straightforward pattern: stricter moderation settings reduce the chance of exposing personal information, but they also limit how much the model engages in conversation. In contrast, more relaxed settings allow longer and richer interactions, which improve scam detection, but at the cost of higher privacy risk. To our knowledge, this is the first framework to unify real-time scam-baiting, federated privacy preservation, and calibrated safety moderation into a proactive defense paradigm.

arXiv:2511.05610v2 Announce Type: replace-cross Abstract: Digital Twins (DTs) for Water Distribution Networks (WDNs) require accurate state estimation with limited sensors. Uniform sampling often wastes resources across nodes with different uncertainty. We propose an adaptive framework combining LSTM forecasting and Conformal Prediction (CP) to estimate node-wise uncertainty and focus sensing on the most uncertain points. Marginal CP is used for its low computational cost, suitable for real-time DTs. Experiments on Hanoi, Net3, and CTOWN show 33--34\% lower demand error than uniform sampling at 40\% coverage and maintain 89.4--90.2\% empirical coverage with only 5--10\% extra computation.

arXiv:2601.01576v2 Announce Type: replace-cross Abstract: Evaluating novelty is critical yet challenging in peer review, as reviewers must assess submissions against a vast, rapidly evolving literature. This report presents OpenNovelty, an LLM-powered agentic system for transparent, evidence-based novelty analysis. The system operates through four phases: (1) extracting the core task and contribution claims to generate retrieval queries; (2) retrieving relevant prior work based on extracted queries via semantic search engine; (3) constructing a hierarchical taxonomy of core-task-related work and performing contribution-level full-text comparisons against each contribution; and (4) synthesizing all analyses into a structured novelty report with explicit citations and evidence snippets. Unlike naive LLM-based approaches, \textsc{OpenNovelty} grounds all assessments in retrieved real papers, ensuring verifiable judgments. We deploy our system on 500+ ICLR 2026 submissions with all reports publicly available on our website, and preliminary analysis suggests it can identify relevant prior work, including closely related papers that authors may overlook. OpenNovelty aims to empower the research community with a scalable tool that promotes fair, consistent, and evidence-backed peer review.

arXiv:2601.09822v2 Announce Type: replace-cross Abstract: Despite recent advancements in Large Language Models (LLMs), complex Software Engineering (SE) tasks require more collaborative and specialized approaches. This concept paper systematically reviews the emerging paradigm of LLM-based multi-agent systems, examining their applications across the Software Development Life Cycle (SDLC), from requirements engineering and code generation to static code checking, testing, and debugging. We delve into a wide range of topics such as language model selection, SE evaluation benchmarks, state-of-the-art agentic frameworks and communication protocols. Furthermore, we identify key challenges and outline future research opportunities, with a focus on multi-agent orchestration, human-agent coordination, computational cost optimization, and effective data collection. This work aims to provide researchers and practitioners with valuable insights into the current forefront landscape of agentic systems within the software engineering domain.

This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here.

Hello! The newsletter didn’t come out yesterday in honor of MLK Day, but we’re back right after Indiana University became national champions. I also want to know why the maple leaf emoji is used so frequently in patients’ medical charts. Palm over face emoji. Runner emoji, mail emoji: bob.herman@statnews.com.

Read the rest…

© Alex Brandon/AP

Good morning, everyone, and welcome to another working week, at least for those on our side of the pond, where we are returning from an extended holiday break. As usual this means that the predictable routine of online meetings and deadlines has returned. To cope, we are reaching for the tea kettle to have another cuppa. Our choice today is a blend of matcha, gingko, and a few berries. Please feel free to join us. Meanwhile, we have assembled a lengthy menu of items — a baker’s dozen, in fact — in hopes of easing your own journey today. Best of luck, and we hope you conquer the world. …

U.S. pharmaceutical companies are stepping up their campaign for higher drug prices in Europe, in some cases threatening to withhold new medicines if European lawmakers refuse, The Financial Times says. Pfizer chief executive Albert Bourla, the first pharmaceutical boss to announce a pricing agreement with President Trump last year, said the deal forced Pfizer to increase prices abroad. “When [we] do the math, shall we reduce the U.S. price to France’s level or stop supplying France? We [will] stop supplying France,” Bourla told reporters at the annual J.P. Morgan Healthcare Conference last week. “So they will stay without new medicines. The system will force us not to be able to accept the lower prices.” Other pharmaceutical executives said at the conference that they were quietly considering withholding or delaying drug launches in Europe.

Chinese drugmakers signed a record $135.7 billion in cross-border out-licensing deals in 2025, as global pharmaceutical giants raced to tap China’s growing drug pipeline, Nikkei Asia reports. The sector completed 157 such deals throughout the year, a sharp rise from the $51.9 billion across 94 deals recorded in 2024, according to Chinese data provider PharmCube’s NextPharma database. Pharmaceutical out-licensing typically grants overseas partners some or all of the rights to develop, manufacture, and commercialize a treatment originally developed by the licenser. The surge underscores China’s evolving role as a critical supply center for the global pharmaceutical industry, where multinational corporations are increasingly hunting for assets in fast-growing fields like antibody-drug conjugates and immunotherapy to offset looming patent cliffs, even as domestic firms grapple with the sustainability of these partnerships.

Continue to STAT+ to read the full story…

© Alex Hogan/STAT

npj Digital Medicine, Published online: 20 January 2026; doi:10.1038/s41746-025-02180-2

An artificial intelligence-powered learning health system to improve sepsis detection and quality of care: a before-and-after study

npj Digital Medicine, Published online: 20 January 2026; doi:10.1038/s41746-026-02337-7

Clinically-guided models or foundation models? predicting cervical spondylotic myelopathy from electronic health records

arXiv:2601.10718v1 Announce Type: new Abstract: Human papillomavirus (HPV) vaccine hesitancy poses significant public health challenges, particularly in Japan where proactive vaccination recommendations were suspended from 2013 to 2021. The resulting information gap is exacerbated by misinformation on social media, and traditional ways cannot simultaneously address individual queries while monitoring population-level discourse. This study aimed to develop a dual-purpose AI agent system that provides verified HPV vaccine information through a conversational interface while generating analytical reports for medical institutions based on user interactions and social media. We implemented a system comprising: a vector database integrating academic papers, government sources, news media, and social media; a Retrieval-Augmented Generation chatbot using ReAct agent architecture with multi-tool orchestration across five knowledge sources; and an automated report generation system with modules for news analysis, research synthesis, social media sentiment analysis, and user interaction pattern identification. Performance was assessed using a 0-5 scoring scale. For single-turn evaluation, the chatbot achieved mean scores of 4.83 for relevance, 4.89 for routing, 4.50 for reference quality, 4.90 for correctness, and 4.88 for professional identity (overall 4.80). Multi-turn evaluation yielded higher scores: context retention 4.94, topic coherence 5.00, and overall 4.98. The report generation system achieved completeness 4.00-5.00, correctness 4.00-5.00, and helpfulness 3.67-5.00, with reference validity 5.00 across all periods. This study demonstrates the feasibility of an integrated AI agent system for bidirectional HPV vaccine communication. The architecture enables verified information delivery with source attribution while providing systematic public discourse analysis, with a transferable framework for adaptation to other medical contexts.

arXiv:2601.11505v1 Announce Type: cross Abstract: Progress in Type 1 Diabetes (T1D) algorithm development is limited by the fragmentation and lack of standardization across existing T1D management datasets. Current datasets differ substantially in structure and are time-consuming to access and process, which impedes data integration and reduces the comparability and generalizability of algorithmic developments. This work aims to establish a unified and accessible data resource for T1D algorithm development. Multiple publicly available T1D datasets were consolidated into a unified resource, termed the MetaboNet dataset. Inclusion required the availability of both continuous glucose monitoring (CGM) data and corresponding insulin pump dosing records. Additionally, auxiliary information such as reported carbohydrate intake and physical activity was retained when present. The MetaboNet dataset comprises 3135 subjects and 1228 patient-years of overlapping CGM and insulin data, making it substantially larger than existing standalone benchmark datasets. The resource is distributed as a fully public subset available for immediate download at https://metabo-net.org/ , and with a Data Use Agreement (DUA)-restricted subset accessible through their respective application processes. For the datasets in the latter subset, processing pipelines are provided to automatically convert the data into the standardized MetaboNet format. A consolidated public dataset for T1D research is presented, and the access pathways for both its unrestricted and DUA-governed components are described. The resulting dataset covers a broad range of glycemic profiles and demographics and thus can yield more generalizable algorithmic performance than individual datasets.